$1.89
5.17% today
Nasdaq, Oct 07, 07:16 pm CET
ISIN
US7574681034
Symbol
RDHL

RedHill Biopharma Ltd. Sponsored ADR Stock price

$1.99
+0.55 38.19% 1M
-0.06 2.93% 6M
-4.22 67.95% YTD
-6.31 76.02% 1Y
-611.31 99.68% 3Y
-9,448.01 99.98% 5Y
-12,358.01 99.98% 10Y
-11,098.01 99.98% 20Y
Nasdaq, Closing price Mon, Oct 06 2025
+0.09 4.74%
ISIN
US7574681034
Symbol
RDHL
Industry

Key metrics

Basic
Market capitalization
$6.3m
Enterprise Value
$2.1m
Net debt
positive
Cash
$4.6m
Shares outstanding
12.9b
Valuation (TTM | estimate)
P/E
- | -
P/S
0.6 | 0.2
EV/Sales
0.2 | 0.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-26.0%
Return on Equity
176.6%
ROCE
551.7%
ROIC
-
Debt/Equity
-0.1
Financials (TTM | estimate)
Revenue
$10.6m | $38.8m
EBITDA
$-22.4m | -
EBIT
$-23.1m | $-6.6m
Net Income
$-11.4m | -
Free Cash Flow
$-9.4m
Growth (TTM | estimate)
Revenue
-11.0% | 382.1%
EBITDA
-157.1% | -
EBIT
-161.8% | 54.6%
Net Income
-115.2% | -
Free Cash Flow
73.8%
Margin (TTM | estimate)
Gross
56.7%
EBITDA
-211.4% | -
EBIT
-217.3%
Net
-107.0% | -
Free Cash Flow
-88.4%
More
EPS
$0.0
FCF per Share
$0.0
Short interest
1.2%
Employees
35
Rev per Employee
$230.0k
Show more

Is RedHill Biopharma Ltd. Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

RedHill Biopharma Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a RedHill Biopharma Ltd. Sponsored ADR forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a RedHill Biopharma Ltd. Sponsored ADR forecast:

Buy
86%
Hold
14%

Financial data from RedHill Biopharma Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
11 11
11% 11%
100%
- Direct Costs 4.60 4.60
22% 22%
43%
6.02 6.02
0% 0%
57%
- Selling and Administrative Expenses 24 24
51% 51%
230%
- Research and Development Expense 2.25 2.25
62% 62%
21%
-22 -22
157% 157%
-211%
- Depreciation and Amortization 0.62 0.62
69% 69%
6%
EBIT (Operating Income) EBIT -23 -23
162% 162%
-217%
Net Profit -11 -11
115% 115%
-107%

In millions USD.

Don't miss a Thing! We will send you all news about RedHill Biopharma Ltd. Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

RedHill Biopharma Ltd. Sponsored ADR Stock News

Neutral
PRNewsWire
one day ago
The deal aims to accelerate Talicia's entry into new Middle East markets  Under the terms of the agreement RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months, plus a minimum of $1.3 million in near-term potential milestone payments, as well as tiered royalties up to mid-teens percent on Talicia net sales...
Neutral
PRNewsWire
8 days ago
The New York Supreme Court has, on appeal, upheld its original summary judgment ruling in favor of RedHill The New York Supreme Court unequivocally dismissed Kukbo Co. Ltd's ("Kukbo") defense again, further ruling that RedHill had fulfilled its agreement obligations even after Kukbo's breach RedHill has been granted approximately $10 million in total awards comprised of the $8.25 million origin...
Neutral
PRNewsWire
about one month ago
Extensive strategic, financial and operational overhaul has reshaped and refocused our business; Strong progress on multiple fronts Commercial and R&D Highlights: Recruitment initiated in the Bayer-supported Phase 2 combination study of opaganib and darolutamide in advanced prostate cancer Positive U.S. Food and Drug Administration (FDA) feedback on pathway to approval for RedHill's next-genera...
More RedHill Biopharma Ltd. Sponsored ADR News

Company Profile

RedHill Biopharma Ltd. is a biopharmaceutical company focusing on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company's subsidiary in the United States. The Research & Development segment includes all activities related to the research and development of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Head office Israel
CEO Dror Ben-Asher
Employees 35
Founded 2009
Website www.redhillbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today